|
?:abstract
|
-
The first case of COVID-19 was diagnosed in St Petersburg on March 2, 2020;the period of increase in the incidence lasted for 10 weeks, the maximum rates were recorded in mid-May, and subsequently there was a statistically significant decrease in the incidence Objective: to determine the level and structure of community immunity to SARS-CoV-2 among the population of St Petersburg during the period of intensive spread of COVID-19 Materials and methods Selection of volunteers for the study was carried out through interviewing and randomization The exclusion criterion was active COVID-19 infection at the time of the survey 2713 people aged 1 to 70 years and above were examined for the presence of specific antibodies to SARS-CoV-2 Antibodies were detected by enzyme immunoassay Results and discussion Studies have shown that in St Petersburg, in the active phase of COVID-19 epidemic, there was a moderate seroprevalence to SARS-CoV-2, which amounted to 26 %, against the background of a high frequency (84 5 %) of asymptomatic infection in seropositive individuals who did not have a history of COVID-19 disease, positive PCR result and ARI symptoms on the day of examination The maximum indicators of herd immunity were established in children 1–6 years old (31 1 %), 7–13 years old (37 7 %) and people over 70 years old (30 4 %) Differences in the level of seroprevalence in the age groups of 18–49 years are statistically significant The highest level of seroprevalence was found among the unemployed (29 7 %), healthcare workers (27 1 %), education sector (26 4 %) and business sector personnel (25 %) In convalescents, COVID-19 antibodies are produced in 75 % of cases In individuals with positive result of PCR analysis carried out earlier, antibodies are detected in 70 % of the cases The results of the study of herd immunity to SARS-CoV-2 are essential to forecast the development of the epidemiological situation, as well as to plan measures for specific and non-specific prevention of COVID-19 © 2020 Russian Research Anti-Plague Institute All rights reserved
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}